Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi, and six major health systems.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
As the United Kingdom nears closer to exiting the European Union without a deal, drug manufacturers such as Novartis are preparing contingencies for how they will continue to provide medications – many of them life-saving – for patients in the U.K.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.
JLL’s life sciences experts anticipate that Big Pharma during 2019 will adopt agile real estate strategies and more entrepreneurial approaches to reinvent R&D and compete with smaller enterprises that are doubling down on product innovation and delivery.
Months after securing $72 million in a Series C financing round and expanding a developmental agreement with pharma giant Roche worth up to $1 billion, SQZ Biotech is expanding the company’s footprint in Watertown, Mass.
Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January 2019, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters.
A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.